News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Affymax, Inc. Drops on Anemia Drug Hematide/Peginesatide Safety Concerns
June 21, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Affymax Inc said its experimental drug for the treatment of anemia in patients with chronic renal failure met the main goal of four late-stage trials.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
MORE ON THIS TOPIC
IN PARTNERSHIP WITH IQVIA
AI Is Taking Over Drug Safety Monitoring–But There’s One Thing It Can’t Replace
July 17, 2025
·
1 min read
·
Lori Ellis
Neuropsychiatric disorders
Otsuka, Lundbeck’s PTSD Bid for Rexulti Hits Speedbump as FDA Questions Efficacy
July 17, 2025
·
2 min read
·
Tristan Manalac
IN PARTNERSHIP WITH EVOTEC
Webinar: Pharma Industry in Crisis
July 16, 2025
·
1 min read
·
BioSpace Insights
Rare diseases
AstraZeneca’s Amyloidosis Asset Stumbles in Late-Stage Trials
July 16, 2025
·
1 min read
·
Dan Samorodnitsky
